A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)

• Published in: European journal of heart failure Vol. 21; no. 5; pp. 665 - 675
• Main Authors: McMurray, John J.V., DeMets, David L., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna M., Martinez, Felipe A., Bengtsson, Olof, Ponikowski, Piotr, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D., McMurray, John JV, DeMets, David L, Inzucchi, Silvio E, Kosiborod, Mikhail N, Langkilde, Anna Maria, Martinez, Felipe A, Sabatine, Marc S, Solomon, Scott D, Diez, Mirta, Nicolau, Jose, Katova, Tzvetana, O'Meara, Eileen, Howlett, Jonathan, Verma, Subodh, Ge, Junbo, Belohlavek, Jan, Schou, Morten, Böhm, Michael, Merkely, Bela, Chopra, Vijay, Kitakaze, Masafumi, de Boer, Rudolf A., Drozdz, Jaroslaw, Tereshchenko, Sergey, Dukat, Andrej, Ljungman, Charlotta, Chiang, Chern‐En, Petrie, Mark, Desai, Akshay, Anand, Inder, Pham, Vinh Nguyen, Pfeffer, Marc A., Pocock, Stuart, Swedberg, Karl, Rouleau, Jean L., Chaturvedi, Nishi, Ivanovich, Peter, Levey, Andrew S., Christ‐Schmidt, Heidi, Held, Claes, Varenhorst, Christoph, Christersson, Christina, Mann, Johannes, Holmgren, Pernilla, Hallberg, Theresa, Langkilde, AnnaMaria, Denison, Hans, Reicher, Barry, Fox, Ywonne, Forsby, Mikael, Alenhag, Eva‐Lena, Nilsson, Ann, Kazanowska, Kinga, Olofsson, Eva Lavik, Karup, Cathrine, Ekedahl‐Berggren, Maria, Klockargård, Anna‐Lena, Kempe, Karin, Selvén, Mathilda
• Format: Journal Article
• Language: English
• Published: Oxford, UK John Wiley & Sons, Ltd 01.05.2019
• Subjects: Benzhydryl Compounds - therapeutic use; Cardiovascular Diseases - mortality; Chronic Disease; Clinical trial; Diabetes Mellitus, Type 2 - complications; Double-Blind Method; Glucosides - therapeutic use; Heart failure; Heart Failure - blood; Heart Failure - complications; Heart Failure - drug therapy; Heart Failure - physiopathology; Hospitalization - statistics & numerical data; Humans; Natriuretic Peptide, Brain - blood; Patient Reported Outcome Measures; Peptide Fragments - blood; Sodium-glucose co-transporter 2 inhibitor; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Stroke Volume; Study Design; Trial Designs; Type 2 diabetes mellitus; Heart failure; Clinical trial; Type 2 diabetes mellitus; Sodium-glucose co-transporter 2 inhibitor

Background Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have been shown to reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes who have, or are at high risk of, cardiovascular disease. Most patients in these trials did not have heart failure at baselin...